Cellergy Therapeutics

Company Overview

Snapshot

Founded in May 2021, Cellergy Therapeutics operates with 1-10 employees. The company has secured one funding round from two investors, XT Group and Fresh Fund, and is focused on advancing its mitochondrial transplantation therapy. In May 2025, Cellergy Therapeutics received $1.5 million from the Israel Innovation Authority to support its pioneering work in regenerative medicine.

Business overview

Cellergy Therapeutics is a biotechnology company focused on developing mitochondrial transplantation therapy to treat degenerative and metabolic diseases. The company produces large quantities of mitochondrial product from human primary sources for systemic, repeated administration, delivering fully matched allogeneic purified mitochondria via IV. This innovative approach aims to restore cellular energy production and enhance cell function, targeting major systemic indications such as CNS disorders, muscle degeneration, and aging. Cellergy operates within the Health Tech & Life Sciences sector, specifically in Pharma & Medical Biotechnology, leveraging biologicals and cell-based technologies.

Strategic signal

In May 2025, Cellergy Therapeutics secured $1.5 million from the Israel Innovation Authority, signaling strong institutional validation for its breakthrough mitochondrial therapy. This funding, alongside plans for clinical trials within a year at Schneider Childrens Medical Center, indicates a significant step towards commercialization and addresses critical challenges in scaling production of high-functioning mitochondria. This development positions Cellergy as a key innovator in regenerative medicine, attracting investor interest in its potential to treat congenital mitochondrial disorders and broader degenerative diseases.

Company Intelligence Q&A

What is Cellergy Therapeutics' core focus?

Cellergy Therapeutics is focused on developing mitochondrial transplantation therapy to restore cellular energy and treat degenerative and metabolic diseases by replacing compromised mitochondria with functional ones.

When was Cellergy Therapeutics founded?

Cellergy Therapeutics was founded in May 2021.

Which investors participated in Cellergy Therapeutics' funding round in September 2025?

In September 2025, Cellergy Therapeutics received funding from XT Group and Fresh Fund.

What significant funding did Cellergy Therapeutics receive in May 2025?

In May 2025, Cellergy Therapeutics secured $1.5 million from the Israel Innovation Authority to advance its mitochondrial therapy.

What is the current employee count for Cellergy Therapeutics?

Cellergy Therapeutics has 1-10 employees.